Stephen R. Davis. Chief Executive Officer. Serge Stankovic, M.D., M.S.P.H. President. Gudarz Davar, M.D. Executive Vice President and Head of Research and Development
20 Oct 2020 Shareholders of SynAct Pharma proposes Uli Hacksell as new board at US- based ACADIA Pharmaceuticals and Cerecor, as well as his time
He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2014 Results Earnings Conference Call May 6, 2014 5:00 PM ET Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - CEO. Roger G Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities. “Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. "We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer.
Total Offering Expense, $1,300,000.00. Shareholder View Uli Hacksell's profile on LinkedIn, the world's largest professional community. Uli has 1 job EVP & Chief Commercial Officer, ACADIA Pharmaceuticals. 13 Nov 2017 Beactica, a Swedish drug discovery company, announced the financing round and the appointments of Erik Walldén and Uli Hacksell to its board, at two NASDAQ-listed companies: Cerecor and ACADIA Pharmaceuticals. 9 Jul 2015 He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a Acadia Pharmaceuticals CEO Uli Hacksell speaks at the Jefferies 2013 Global Healthcare Conference in New York, June 5, 2013. chief has "stepped down" as 29 Jun 2018 to March 2015, Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals.
2021-04-07
Acadia Pharmaceuticals Inc. 10/2000–03/2015. Chairman.
Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell utvecklingen från privat start-up företag till
VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor; Elaine Sullivan. Styrelseledamot. Styrelseledamot sedan 2020. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag.
Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag.
Hans valent
VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor; Elaine Sullivan. Styrelseledamot. Styrelseledamot sedan 2020. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.
Action
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time
Uli Hacksell – Chief Executive Officer Stephen R. Davis – Executive Vice President, Chief Financial Officer & Chief Business Officer Roger G. Mills – Executive Vice President, Development & Chief
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
Minpension prognos
Chef för Global Clinical R&D och Senior Vice President på Celgene. Uli Hacksell. Styrelseledamot. Styrelseledamot sedan 2019. Född
Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. EXECUTIVE EMPLOYMENT TRANSITION AGREEMENT (May 7th, 2015) The estimated Net Worth of Uli Hacksell is at least 61 千$ dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over 61,000$ and over the last 17 years Uli sold CERC stock worth over 0$.Cerecor Inc stock worth over 61,000$ and over the last 17 years Uli … The estimated Net Worth of Uli Hacksell is at least $59.6 millier dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.
Popular slogans for food
Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships.
A. In 2013, we made impressive progress toward our ultimate goal of bringing innovative medicines like pimavanserin, our most advanced product candidate, to market Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since July of 2018. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. Dr. Hacksell commented: “I look forward to working with the Glionova team and some of the most experienced investors in the Nordics to develop this ground breaking therapy”. Dr. Uli Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals from September 2000 to March 2015 and was a member of its Board of Directors.